Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Friday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.

Arcadia Biosciences Price Performance

Shares of RKDA stock opened at $3.86 on Friday. The company has a market capitalization of $5.26 million, a P/E ratio of -0.90 and a beta of 1.27. The company’s 50-day simple moving average is $3.34 and its two-hundred day simple moving average is $3.01. Arcadia Biosciences has a one year low of $1.85 and a one year high of $5.34.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative return on equity of 51.00% and a negative net margin of 110.61%. During the same quarter in the previous year, the business earned ($2.64) earnings per share. On average, research analysts expect that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.